Company profile
Passage BIO, Inc.
NASDAQ:PASGBiotechnology: Biological Products (No Diagnostic Substances)
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04747431 | phase1_2 | active_not_recruiting | 2021-09-14 | 2028-08-01 | Passage Bio, Inc. | A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes |
FDA applications (0)
No records yet.